Beractanto

Beractanto is the active substance in a pulmonary surfactant medicine known commercially as Survanta.

This drug, for intratracheal use, is indicated for the treatment of newborn children with respiratory distress syndrome, since its action increases the elasticity of the lung and improves its functioning.

Beractanto is produced by the Abbott laboratory.

Indications of Beractanto

Beractanto is indicated for the prophylaxis and treatment of respiratory distress syndrome, also called hyaline membrane disease in newborns and premature infants.

How to use Beractanto

The mode of use of Beractanto consists of the administration of 100 mg per kg to newborn babies, intratracheally.

Treatment should be started as early as possible. Prevention should be started at least 15 minutes after delivery and rescue before completing 8 hours of life.

Four doses of the drug can be administered in the first 48 hours of life, at intervals of 6 hours to 12 hours.

Side effects of Beractanto

Side effects of Beractanto can be a decrease in heart rate, a decrease in the concentration of oxygen in the blood, a decrease in brain electrical activity and an increased risk of pulmonary hemorrhage.